Intratumoral injection of lipiodol pingyangmycin combined with thalidomide in treatment of recurrent advanced liver cancer

XU Lu,FENG Long,JIANG Wei-min,LI Ling

DOI: https://doi.org/10.3969/j.issn.1006-5725.2010.11.055

2010-01-01

Abstract:Objective To explore an economical and safe therapy for the patients with recurrent advanced liver cancer who had been treated by TACE but no longer suitable for it.Methods 55 patients were assigned to receive either intratumoral injections of pingyangmycin of 8 to 16 mg completely emulsified with UFL of 5 to 10 mL and oral thalidomide of 50mg thrice daily for 14 days(study group) or best supportive care plus common traditional Chinese medicines for cancer(control group).Survival time was the primary endpoint and time to disease progression was the secondary endpoint.Statistical software Spss11.5 was used to analyze survival and to conduct χ2 test.Results 3-, 6-, or 12-months survival and median survival time differed significantly betwewn the two groups(81.1% vs.60.0% , 64.9% vs.36.0% or 9.2% vs.5.1%;7.92 months vs.5.25 months;P= 0.0465).In the study group, the disease was stable for 3 months but then started to develop 3 months later in 8 patients(29.6.0%), and the disease was stable and no new lesions occurred in 7(25.9%), the rate of profit was 55.5(29.6 ± 25.9)%.In the control group, the disease was stable for 3 months but then started to develop 3 months later in 4 patients(14.3%), and the disease was stable and no new lesions occurred in 4(14.3%), the rate of profit was 28.6(14.3 ± 14.3)%.There was a significant difference in the rate of profit between the two groups(P = 0.043).Conclusions Intratumoral injection of lipiodol pingyangmycin combined with thalidomide is superior to the supportive therapy plus Chinese medicines in the survival and rate of profit.It is sample, feasible, economical, safe, particularlly suitable for primary care units,and worth to further study.